During the corresponding time, Ars Pharmaceuticals Inc recorded a revenue increase by 114.15 % year on year, sequentially revenue grew by 48.4 %. While revenue at the Ars Pharmaceuticals Inc 's corporate clients
Ars Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company operates under various regulatory frameworks governing personal data processing, including the California Consumer Privacy Act (CCPA), California Privacy Rights Act (CPRA), the European Union General Data Protection Regulation (EU GDPR), and the United Kingdom GDPR. These laws impose compliance obligations on entities handling personal information of California residents and data subjects within the European Economic Area (EEA). The CCPA and CPRA establish privacy and security requirements, disclosure mandates, opt-out rights, and enforcement mechanisms related to personal information of California residents. The EU GDPR applies to companies established both within and outside the EEA that process personal data connected to offering goods or services or monitoring the behavior of data subjects in the EEA. Its requirements include limitations on data processing, legal bases for processing, transparency obligations, appointment of data protection officers, conducting impact assessments, consent standards, implementation of safeguards, breach notification protocols, and designation of representatives. The company’s relevant customer segments include California residents and data subjects in the EEA.
The biopharmaceutical landscape is characterized by innovation, competition, and financial accountability. ARS Pharmaceuticals Inc. has recently gained attention with the announcement of its epinephrine nasal spray, neffy, being included in Express Scripts Commercial National Formularies. While this development expands access to crucial allergy treatment for patients and caregivers, the company faces financial headwinds that merit consideration. Access to Neffy: A Step Forward for Allergy Management As of November 22, 2024, neffy, the first epinephrine nasal spray, has been included in Express Scripts commercial formularies. This inclusion is significant as it facilitates broader accessibility for patients...
In an unprecedented advancement in the realm of pediatric healthcare, ARS Pharmaceuticals has formally submitted a supplemental New Drug Application (sNDA) to the esteemed Food and Drug Administration (FDA) in regard to its innovative product, neffy. This particular formulation, comprising a dosage of 1 milligram, targets the vital need for timely intervention in Type I allergic reactions among younger patients, specifically those weighing between 15 and 30 kilograms, equivalent to 33 to 66 pounds.The potential approval of neffy 1 mg is a momentous step forward, as it is poised to become the first and, indeed, the singular needle-free epinephrine treatment available for children of school age who are afflict...
ARS Pharmaceuticals, a biopharmaceutical company dedicated to providing solutions for severe allergic reactions, has recently submitted its response to the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for neffy (epinephrine nasal spray). This innovative product aims to offer a quick and effective treatment for Type I allergic reactions, including life-threatening anaphylaxis.Anaphylaxis, a severe and potentially fatal allergic reaction, requires immediate medical attention. It can be triggered by various allergens, such as certain foods, insect bites, medications, or even latex. The symptoms can range from hives, swelling, and difficulty breathing to a drop in blood pressu...
Revolutionary Epinephrine Nasal Spray to Be Showcased at Prestigious AAAAI Annual MeetingSAN DIEGO, Feb. 05, 2024 - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a pioneering biopharmaceutical company committed to providing enhanced protection against severe allergic reactions and anaphylaxis, is excited to announce the upcoming presentation of groundbreaking clinical data at the highly anticipated 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The event, scheduled to take place from February 23 to February 26, 2024, in Washington, DC, will showcase the efficacy outcomes and strong benefits of neffy (epinephrine nasal spray).Neffy, the innovative epinephrine nasal spray developed...
Ars Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company operates under various regulatory frameworks governing personal data processing, including the California Consumer Privacy Act (CCPA), California Privacy Rights Act (CPRA), the European Union General Data Protection Regulation (EU GDPR), and the United Kingdom GDPR. These laws impose compliance obligations on entities handling personal information of California residents and data subjects within the European Economic Area (EEA). The CCPA and CPRA establish privacy and security requirements, disclosure mandates, opt-out rights, and enforcement mechanisms related to personal information of California residents. The EU GDPR applies to companies established both within and outside the EEA that process personal data connected to offering goods or services or monitoring the behavior of data subjects in the EEA. Its requirements include limitations on data processing, legal bases for processing, transparency obligations, appointment of data protection officers, conducting impact assessments, consent standards, implementation of safeguards, breach notification protocols, and designation of representatives. The company’s relevant customer segments include California residents and data subjects in the EEA.
Sources:
Ars Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ars Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ars Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
129.72 %